You are here

Article info

Article menu
Download PDFPDF
Inflammatory bowel disease
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis

Authors

  1. Correspondence to Dr William J Sandborn, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; sandborn.william{at}mayo.edu
View Full Text

Citation

Sandborn WJ, Colombel JF, Frankel M, et al
Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis
Gut 2010;59:1485-1492.

Publication history

  • Revised July 1, 2010
  • Accepted July 2, 2010
  • First published October 14, 2010.
Online issue publication 
April 18, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.